VistaGen Therapeutics PS Ratio

: 132.50 (As of Today)

View and export this data going back to 2011. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, VistaGen Therapeutics's share price is $1.06. VistaGen Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $0.01. Hence, VistaGen Therapeutics's PS Ratio for today is 132.50.

Good Sign:

VistaGen Therapeutics Inc stock PS Ratio (=132.5) is close to 1-year low of 131.25

The historical rank and industry rank for VistaGen Therapeutics's PS Ratio or its related term are showing as below:

VTGN' s PS Ratio Range Over the Past 10 Years
Min: 2.01 Med: 27.2 Max: 328.89
Current: 132.5

During the past 13 years, VistaGen Therapeutics's highest PS Ratio was 328.89. The lowest was 2.01. And the median was 27.20.

VTGN's PS Ratio is ranked worse than
86.34% of 1010 companies
in the Biotechnology industry
Industry Median: 11.21 vs VTGN: 132.50

VistaGen Therapeutics's Revenue per Sharefor the three months ended in Dec. 2021 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $0.01.

Warning Sign:

VistaGen Therapeutics Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of VistaGen Therapeutics was -11.10% per year.

During the past 13 years, VistaGen Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -100.00% per year. The lowest was -100.00% per year. And the median was -100.00% per year.

Back to Basics: PS Ratio

VistaGen Therapeutics PS Ratio Historical Data

The historical data trend for VistaGen Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

PS Ratio

11.81

163.85

VistaGen Therapeutics Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
PS Ratio																215.56	163.85	242.31	274.00	243.75

Competitive Comparison

For the Biotechnology subindustry, VistaGen Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

VistaGen Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where VistaGen Therapeutics's PS Ratio falls into.

VistaGen Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

VistaGen Therapeutics's PS Ratio for today is calculated as

PS Ratio	=	Share Price	/	Revenue per Share (TTM)
	=	1.06	/	0.008
	=	132.50

VistaGen Therapeutics's Share Price of today is $1.06.
VistaGen Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

It can also be calculated from the numbers for the whole company:

PS Ratio

Market Cap

Revenue

The Revenue here is for the trailing 12 months.

VistaGen Therapeutics (NAS:VTGN) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.

Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.

VistaGen Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

VistaGen Therapeutics Business Description

Industry

Healthcare » Biotechnology NAICS : 325412 SIC : 2834

Comparable Companies

NAS:ALT NAS:MGNX NAS:TRDA NAS:KALV NAS:JNCE NAS:STRO AMEX:LCTX NAS:XOMA NAS:GTHX NAS:NVCT OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Executives

Saxe Jon S	director	FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane	officer: VP, CFO AND SECRETARY	5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph	director, officer: PRES./CHIEF SCIENTIFIC OFFICER	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan	officer: CHIEF MEDICAL OFFICER	343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A.	officer: VP CORPORATE DEVELOPMENT	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B	director	343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J.	director	C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle	director	255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin	officer: VP CORPORATE DEVELOPMENT	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A.	director	384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie	director, 10 percent owner, officer: PRESIDENT	13834 W. HOYT ROAD RATHDRUM ID 83858